| Pharmaceutical Information |
| Drug Name |
Sincalide |
| Drug ID |
BADD_D02027 |
| Description |
Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK-8_. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion in the body. When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Furthermore, sincalide stimulates pancreatic secretion of bicarbonate and enzymes.
As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. |
| Indications and Usage |
As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. |
| Marketing Status |
approved |
| ATC Code |
V04CC03 |
| DrugBank ID |
DB09142
|
| KEGG ID |
D05845
|
| MeSH ID |
D012844
|
| PubChem ID |
9833444
|
| TTD Drug ID |
D0I8AF
|
| NDC Product Code |
82773-004; 0270-0556; 55463-0004; 73309-028; 69766-102; 69575-4029; 63323-579; 72266-248; 42973-235; 70511-131 |
| UNII |
M03GIQ7Z6P
|
| Synonyms |
Sincalide | CCK-OP | OP-CCK | H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 | Cholecystokinin Pancreozymin C-Terminal Octapeptide | Cholecystokinin Pancreozymin C Terminal Octapeptide | Syncalide | CCK-8 | Cholecystokinin Octapeptide | SQ-19,844 | SQ 19,844 | SQ19,844 | SQ-19844 | SQ 19844 | SQ19844 | Kinevac |
|
| Chemical Information |
| Molecular Formula |
C49H62N10O16S3 |
| CAS Registry Number |
25126-32-3 |
| SMILES |
CSCCC(C(=O)NCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3
=CC=CC=C3)C(=O)N)NC(=O)C(CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)C(CC(=O)O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
